IL17A and psoriasis: In our research, we analyzed how clinical and inflammatory aspects, such as BMI, triglycerides, glycemia, leptin, SII and the cytokines IL-17A and IL-23, influence quality of life as measured by DLQI, in psoriasis patients after one year of treatment.